PGIM India Midcap Opportunities mutual fund review: Should you invest?

ET Wealth collaborates with Value Research to analyse top mutual funds. We examine the key fundamentals of the fund, its portfolio and performance to help you make an informed investment decision.

BASIC FACTS
DATE OF LAUNCH
12 FEBRUARY 2013
CATEGORY

EQUITY
TYPE
MID CAP
AUM*
Rs.7,558 Crore
BENCHMARK
NIFTY MIDCAP 150 TOTAL
RETURN INDEX

WHAT IT COSTS
NAV**
GROWTH OPTION
Rs.43.27
IDCW
Rs.22.2
MINIMUM INVESTMENT
Rs.5,000
MINIMUM SIP AMOUNT
Rs.1,000
EXPENSE RATIO*** (%)
1.93
EXIT LOAD
0.5% for redemption within 90 days
*AS ON 31 DECEMBER 2022
**AS ON 17 JANUARY 2023
***AS ON 30 NOVEMBER 2022

FUND MANAGER
ANIRUDDHA NAHA
TENURE: 4 YEARS, 8 MONTHS

Recent portfolio changes
New Entrants: Affle (India), Gland Pharma, Max Healthcare Institute, Escorts Kubota, HDFC, Mphasis.

Complete Exits: Bayer CropScience, Gokaldas Exports, L&T Technology Services, MM Forgings, Rolex Rings,Coforge, Praj Industries, UPL.

Should you buy?
A struggling fund under its previous ownership, this fund has strengthened processes under new leadership since the PGIM India takeover. Under its present fund manager, the fund places firm emphasis on low debt, strong cash flows and clean corporate governance track record. It avoid bets on sectors with high or rising competitive intensity. The fund manager prefers running an index agnostic portfolio. Its performance has shown a remarkable turnaround since 2018, and now boasts a superior risk-return profile in its category. While it has lagged over the past year, the fund’s refined approach and quality leadership lends comfort for the long term.

(Source: Value Research)